AANS publishes analysis of final 2027 outpatient payment rule
AANS highlights payment redistribution and implications for neurosurgery in the final 2027 Medicare outpatient and ASC rule.

AANS publishes its analysis of the final 2027 rule
The American Association of Neurological Surgeons published its summary and analysis of the final calendar year 2027 Medicare outpatient and ambulatory surgical center payment rule on November 18, 2026, highlighting payment redistribution and provisions affecting neurosurgical services.
According to AANS, CMS issued final rule CMS-1850-FC on November 4, 2026. The rule updates payment rates and quality reporting requirements for hospital outpatient departments and ambulatory surgical centers for calendar year 2027.
CMS estimates that the combined effect of the finalized policies will increase overall Hospital Outpatient Prospective Payment System payments by approximately 1.7% in 2027 compared with 2026, AANS reports. That aggregate increase does not represent a uniform adjustment for hospitals or individual services.
Payment redistribution and outpatient technology provisions
AANS identifies changes to 340B drug reimbursement and associated budget-neutrality adjustments as drivers of redistribution between drug and non-drug services and among hospitals. The financial effect therefore depends on hospital type and the payment policies affecting its services, rather than the overall OPPS growth figure alone.
The association also highlights implications for neurosurgery from expanded outpatient surgical options, payments for neuromodulation and emerging technologies, and policies affecting access to hospital-based imaging and procedures.
In its November 17, 2026, report, King & Spalding said CMS finalized an expansion of site-neutral payments to imaging without contrast and continued the phase-out of the Inpatient Only list. These are finalized policy decisions for the 2027 payment framework.
Device and software provisions add another dimension. Medtech Insight reported on November 13, 2026, that the rule approves nine medical devices for transitional pass-through payments and establishes a payment framework for software-based diagnostic services.
What it means
AANS highlights payment redistribution alongside overall payment growth. Its summary says the impact varies considerably by hospital type and payment policy; the estimated 1.7% increase applies to overall OPPS payments, not uniformly to individual hospitals or services.
AANS identifies implications for neuromodulation and emerging technologies, while Medtech Insight separately reports device pass-through payments and a payment framework for software-based diagnostic services. The supplied summaries do not quantify the commercial effects of these provisions.